BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 12856157)

  • 1. Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.
    Jacob T; Grahek D; Younsi N; Kerrou K; Aide N; Montravers F; Balogova S; Colombet C; De Beco V; Talbot JN
    Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1266-9. PubMed ID: 12856157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
    Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
    J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma.
    Liu YL; Lu MY; Chang HH; Lu CC; Lin DT; Jou ST; Yang YL; Lee YL; Huang SF; Jeng YM; Lee H; Miser JS; Lin KH; Liao YF; Hsu WM; Tzen KY
    Oncotarget; 2016 Apr; 7(14):18774-86. PubMed ID: 26959748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer.
    Pandit N; Gonen M; Krug L; Larson SM
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):78-84. PubMed ID: 12483413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data.
    Talbot JN; Kerrou K; Missoum F; Grahek D; Aide N; Lumbroso J; Montravers F
    Mol Imaging Biol; 2005; 7(4):257-61. PubMed ID: 16082495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.
    Tripathi M; Sharma R; D'Souza M; Jaimini A; Panwar P; Varshney R; Datta A; Kumar N; Garg G; Singh D; Grover RK; Mishra AK; Mondal A
    Clin Nucl Med; 2009 Dec; 34(12):878-83. PubMed ID: 20139821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.
    Taïeb D; Tessonnier L; Sebag F; Niccoli-Sire P; Morange I; Colavolpe C; De Micco C; Barlier A; Palazzo FF; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):580-6. PubMed ID: 18394015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
    Santhanam P; Taïeb D
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.
    Karunanithi S; Sharma P; Kumar A; Khangembam BC; Bandopadhyaya GP; Kumar R; Gupta DK; Malhotra A; Bal C
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1025-35. PubMed ID: 23525498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
    Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine.
    Becherer A; Karanikas G; Szabó M; Zettinig G; Asenbaum S; Marosi C; Henk C; Wunderbaldinger P; Czech T; Wadsak W; Kletter K
    Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1561-7. PubMed ID: 14579097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
    Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
    J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited Prognostic Value of SUV max Measured by F-18 FDG PET/CT in Newly Diagnosed Small Cell Lung Cancer Patients.
    Kim SJ; Chang S
    Oncol Res Treat; 2015; 38(11):577-85. PubMed ID: 26599271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer.
    Brink I; Schumacher T; Mix M; Ruhland S; Stoelben E; Digel W; Henke M; Ghanem N; Moser E; Nitzsche EU
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1614-20. PubMed ID: 15258700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.